For patients who received a letter on improperly disclosed information by a claims processing vendor, read more.

Excellence is just the beginning.

Translate

French German Italian Portuguese Russian

Hepatorenal Syndrome Type 1 Treatment Study

Clinical Trial Title: 
A study to confirm the efficacy and safety of adults with hepatorenal syndrome (HRS) type 1 in the treatment of intravenous terlipressin and/or receiving standard of care albumin therapy.
Clinical Trial Protocol ID: 
16030404
Clinical Trial Investigator Name: 
Sujit Janardhan, MD
Clinical Trial Protocol Description: 

An investigational drug is being studied that may help slow down or reverse kidney failure (hepatorenal syndrome [HRS] type 1) in patients with chronic liver disease. Nationwide, 300 patients will be recruited for this study. At Rush University Medical Center we expect to recruit approximately 10 patients. The treatment will be assigned randomly.

Clinical Trial Eligibility Criteria: 

In order to participate you must meet the following criteria:

  • Are at least 18 years of age.
  • Are an adult with cirrhosis (scarring of the liver), ascites (fluid in the abdomen), and a diagnosis of HRS type 1.
  • Have rapidly progressive reduction in renal function.
  • Have confirmation that albumin was given.
  • Pass certain screening tests.

You will be excluded from the study if any of the following criteria apply to you:

  • Have severe cardiovascular disease.
  • Have shock or sepsis.
  • Have a paracentesis > 4L 2 days before.
  • Have (TIPS) within 30 days

This is a partial list of inclusion and exclusion criteria.

Clinical Trial Area: 
Kidney and Urinary System Disorders
Liver, Biliary and Pancreatic Disorders
Contact Phone: 
(312) 942-8910 or (312) 942-1372
Contact Name: 
Sujit Janardhan or Lelani Fetrow